Fine structural variations of αβTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients

Journal of Immunology

Volumn 183, Issue 8, 2009, Pages 5397-5406

  Wieckowski, Sébastien ^a   Baumgaertner, Petra ^a   Corthesy, Patricia ^a   Voelter, Verena ^a   Romero, Pedro ^a   Speiser, Daniel E ^a   Rufer, Nathalie ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; AMINO ACID; GENE PRODUCT; GLUTAMYLLEUCYLALANYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; GLYCYLLEUCYLVALYLALANYLGLYCINE; HLA A ANTIGEN; MELAN A; PEPTIDE DERIVATIVE; RECEPTOR SUBTYPE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; GENE SEQUENCE; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; LYMPHOCYTE STRUCTURE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PRIORITY JOURNAL; PROTEIN MOTIF; RECEPTOR BINDING; VACCINATION;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; AUTOANTIGENS; BASE SEQUENCE; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; MART-1 ANTIGEN; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; PROTEIN CONFORMATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SEQUENCE ALIGNMENT; SKIN NEOPLASMS;

EID: 77954100566     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901460     Document Type: Article

References (52)

1. Gourley, T. S., E. J. Wherry, D. Masopust, and R. Ahmed. 2004. Generation and maintenance of immunological memory. Semin. Immunol. 16: 323-333.
2. Blattman, J. N., R. Antia, D. J. Sourdive, X. Wang, S. M. Kaech, K. Murali-Krishna, J. D. Altman, and R. Ahmed. 2002. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J. Exp. Med. 195: 657-664.
3. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227-2234. (Pubitemid 29288845)
4. Zeh, H. J., 3rd, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162: 989-994.
5. Pass, H. A., S. L. Schwarz, J. R. Wunderlich, and S. A. Rosenberg. 1998. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4: 316-323. (Pubitemid 28452398)
6. Clay, T. M., M. C. Custer, M. D. McKee, M. Parkhurst, P. F. Robbins, K. Kerstann, J. Wunderlich, S. A. Rosenberg, and M. I. Nishimura. 1999. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol. 162: 1749-1755.
7. + T cells in humans. J. Exp. Med. 196: 207-216.
8. Rubio, V., T. B. Stuge, N. Singh, M. R. Betts, J. S. Weber, M. Roederer, and P. P. Lee. 2003. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9: 1377-1382.
9. Stuge, T. B., S. P. Holmes, S. Saharan, A. Tuettenberg, M. Roederer, J. S. Weber, and P. P. Lee. 2004. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 1: e28.
10. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
11. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanomareactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157: 2539-2548.
12. Yu, Z., M. R. Theoret, C. E. Touloukian, D. R. Surman, S. C. Garman, L. Feigenbaum, T. K. Baxter, B. M. Baker, and N. P. Restifo. 2004. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J. Clin. Invest. 114: 551-559.
13. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160: 1750-1758.
14. + T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res. 59: 301-306.
15. + T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin. Cancer Res. 9: 669-677.
16. + T cell responses to vaccination with peptide: IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746.
17. Speiser, D. E., P. Baumgaertner, V. Voelter, E. Devevre, C. Barbey, N. Rufer, and P. Romero. 2008. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA 105: 3849-3854.
18. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
19. Speiser, D. E., P. Baumgaertner, C. Barbey, V. Rubio-Godoy, A. Moulin, P. Corthesy, E. Devevre, P. Y. Dietrich, D. Rimoldi, D. Lienard, et al. 2006. A novel approach to characterize clonality and differentiation of human melanomaspecific T cell responses: spontaneous priming and efficient boosting by vaccination. J. Immunol. 177: 1338-1348.
20. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190: 705-715.
21. + T lymphocytes. J. Immunol. 178: 4112-4119.
22. + T subsets based on gene expression and replicative history analysis. Methods Mol. Med. 109: 265-284.
23. Roux, E., C. Helg, F. Dumont-Girard, B. Chapuis, M. Jeannet, and E. Roosnek. 1996. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 87: 3984-3992.
24. + T cell clonotypes is not limited by replicative senescence or functional alteration. J. Immunol. 179: 2368-2379.
25. Lefranc, M. P., V. Giudicelli, C. Ginestoux, J. Bodmer, W. Muller, R. Bontrop, M. Lemaitre, A. Malik, V. Barbie, and D. Chaume. 1999. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 27: 209-212.
26. Arden, B., S. P. Clark, D. Kabelitz, and T. W. Mak. 1995. Human T-cell receptor variable gene segment families. Immunogenetics 42: 455-500. (Pubitemid 26025063)
27. Lassmann, T., and E. L. Sonnhammer. 2005. Kalign: an accurate and fast multiple sequence alignment algorithm. BMC Bioinformatics 6: 298.
28. Crooks, G. E., G. Hon, J. M. Chandonia, and S. E. Brenner. 2004. WebLogo: a sequence logo generator. Genome Res. 14: 1188-1190.
29. Yousfi Monod, M., V. Giudicelli, D. Chaume, and M. P. Lefranc. 2004. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics 20 Suppl. 1: i379-i385.
30. + T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin. Cancer Res. 7: 766s-772s.
31. Trautmann, L., N. Labarriere, F. Jotereau, V. Karanikas, N. Gervois, T. Connerotte, P. Coulie, and M. Bonneville. 2002. Dominant TCR V α usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur. J. Immunol. 32: 3181-3190.
32. Dietrich, P. Y., F. A. Le Gal, V. Dutoit, M. J. Pittet, L. Trautman, A. Zippelius, I. Cognet, V. Widmer, P. R. Walker, O. Michielin, et al. 2003. Prevalent role of TCR α-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J. Immunol. 170: 5103-5109.
33. Genevee, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (V α 1-w29/V β 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22: 1261-1269.
34. Cole, D. K., F. Yuan, P. J. Rizkallah, J. J. Miles, E. Gostick, D. A. Price, G. F. Gao, B. K. Jakobsen, and A. K. Sewell. 2009. Germline-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J. Biol. Chem. [Epub ahead of print] 2009 Jul 15.
35. Serana, F., A. Sottini, L. Caimi, B. Palermo, P. G. Natali, P. Nistico, and L. Imberti. 2009. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V β and J β chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. J. Transl. Med. 7: 21.
36. Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, and D. C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384: 134-141.
37. Derre, L., M. Bruyninx, P. Baumgaertner, M. Ferber, D. Schmid, A. Leimgruber, V. Zoete, P. Romero, O. Michielin, D. E. Speiser, and N. Rufer. 2008. Distinct sets of αβTCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc. Natl. Acad. Sci. USA 105: 15010-15015.
38. + cytolytic T cells. J. Immunol. 178: 3566-3574.
39. Moss, P. A., R. J. Moots, W. M. Rosenberg, S. J. Rowland-Jones, H. C. Bodmer, A. J. McMichael, and J. I. Bell. 1991. Extensive conservation of α and β chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc. Natl. Acad. Sci. USA 88: 8987-8990.
40. Lehner, P. J., E. C. Wang, P. A. Moss, S. Williams, K. Platt, S. M. Friedman, J. I. Bell, and L. K. Borysiewicz. 1995. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V β 17 gene segment. J. Exp. Med. 181: 79-91.
41. Argaet, V. P., C. W. Schmidt, S. R. Burrows, S. L. Silins, M. G. Kurilla, D. L. Doolan, A. Suhrbier, D. J. Moss, E. Kieff, T. B. Sculley, and I. S. Misko. 1994. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180: 2335-2340.
42. Gillespie, G. M., G. Stewart-Jones, J. Rengasamy, T. Beattie, J. J. Bwayo, F. A. Plummer, R. Kaul, A. J. McMichael, P. Easterbrook, T. Dong, et al. 2006. Strong TCR conservation and altered T cell cross-reactivity characterize a B*57-restricted immune response in HIV-1 infection. J. Immunol. 177: 3893-3902.
43. Borbulevych, O. Y., F. K. Insaidoo, T. K. Baxter, D. J. Powell, Jr., L. A. Johnson, N. P. Restifo, and B. M. Baker. 2007. Structures of MART-126/27-35 peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J. Mol. Biol. 372: 1123-1136.
44. + T cell responses in SIV infection. J. Exp. Med. 206: 923-936.
45. Trautmann, L., M. Rimbert, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. Cerundolo, and M. Bonneville. 2005. Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J. Immunol. 175: 6123-6132.
46. + T cell populations specific for persistent DNA viruses. J. Exp. Med. 202: 1349-1361.
47. Gras, S., X. Saulquin, J. B. Reiser, E. Debeaupuis, K. Echasserieau, A. Kissenpfennig, F. Legoux, A. Chouquet, M. Le Gorrec, P. Machillot, et al. 2009. Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope. J. Immunol. 183: 430-437.
48. Kjer-Nielsen, L., C. S. Clements, A. W. Purcell, A. G. Brooks, J. C. Whisstock, S. R. Burrows, J. McCluskey, and J. Rossjohn. 2003. A structural basis for the selection of dominant αβ T cell receptors in antiviral immunity. Immunity 18: 53-64.
49. Stewart-Jones, G. B., A. J. McMichael, J. I. Bell, D. I. Stuart, and E. Y. Jones. 2003. A structural basis for immunodominant human T cell receptor recognition. Nat. Immunol. 4: 657-663.
50. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107.
51. Gallimore, A., T. Dumrese, H. Hengartner, R. M. Zinkernagel, and H. G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187: 1647-1657.
52. Speiser, D. E., D. Kyburz, U. Stubi, H. Hengartner, and R. M. Zinkernagel. 1992. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities: low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149: 972-980.